Drug intelligence / Profile preview

KinoPharma influenza treatment

Development stage: Preclinical
Lead developer: KinoPharma
Modality: Small Molecules

Overview

KinoPharma's influenza treatment is an antiviral candidate currently in the preclinical stage of development. It is designed to target both Influenza A and Influenza B viruses for the treatment of seasonal influenza. Developed by KinoPharma, the program focuses on small molecule intervention, although the specific molecular target (such as viral polymerase, neuraminidase, or M2 protein) has not been publicly disclosed. The candidate is part of KinoPharma's broader antiviral pipeline which utilizes their proprietary drug discovery platform to address viral pathogens.

Other names: Influenza Treatment

Targets

SRPK/CLK (Serine/arginine-rich protein-specific kinase and CDC-like kinase)

Beyond the preview

Go deeper on KinoPharma influenza treatment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KinoPharma influenza treatment.

Explore the full profile